AAP
HOWL icon

Arax Advisory Partners’s Werewolf Therapeutics HOWL Stock Holding History

Arax Advisory Partners’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12
Closed -$32 – 5234
2026
Q1 		$32 Sell
12
-27
-69% -$18 ﹤0.01% 3691
2025
Q4 		$25 Sell
39
-29
-43% -$35 ﹤0.01% 4007
2025
Q3 		$133 Buy
+68
New +$93 ﹤0.01% 3480

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Arax Advisory Partners's HOWL Position: Q2 2026 in Review

Arax Advisory Partners sold out of Werewolf Therapeutics (HOWL) in Q2 2026, closing a stake of 12 shares — an estimated $32 sold.

Arax Advisory Partners first reported a position in HOWL in Q3 2025 and held it in 3 quarters. The position peaked at $133 in Q3 2025. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

  • Arax Advisory Partners reported no remaining Werewolf Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 12 Werewolf Therapeutics shares in Q2 2026, an estimated $32.
  • Arax Advisory Partners first reported a position in Werewolf Therapeutics in Q3 2025 and held it in 3 quarters.
  • Arax Advisory Partners's Werewolf Therapeutics position peaked at $133 in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.